Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ced.13879 | DOI Listing |
Publication Analysis
Top Keywords
cases perniosis
4
perniosis free
4
free flap
4
flap graft
4
graft site
4
site hands
4
cases
1
free
1
flap
1
graft
1
Similar Publications
[Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses.
Actas Dermosifiliogr
January 2025
Servicio de Dermatología, Hospital de Figueres, Fundació Salut Empordà, Girona, Spain; Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain. Electronic address:
Article Synopsis
- Anifrolumab is a drug that blocks a specific receptor (IFNAR1) and is approved for treating moderate-to-severe systemic lupus erythematosus (SLE).
- * In clinical trials, it has shown effectiveness for skin-related lupus issues, even though it's not specifically approved for cutaneous lupus erythematosus (CLE).
- * Ongoing studies aim to assess its effectiveness for different types of lupus and related conditions, while its common side effects include respiratory infections and herpes zoster.
Systemic complications of Aicardi Goutières syndrome using real-world data.
Mol Genet Metab
October 2024
Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address:
Article Synopsis
- Aicardi Goutières Syndrome (AGS) is a rare genetic disorder characterized by a range of systemic health issues and delayed diagnosis, prompting researchers to analyze longitudinal data from medical records to better understand its burden.* -
- The study included 167 individuals with genetically confirmed AGS, compiling information on demographics, age of onset, and neurological complications; the most frequent genetic mutations associated with AGS were identified.* -
- Results revealed that gastrointestinal issues were the earliest systemic complications, while neurological symptoms such as tone abnormalities and irritability were prevalent, usually manifesting in infancy.*
Chilblain lupus erythematosus triggered by UV nail lamp exposure: A case series. .
Lupus
October 2024
Hospital Militar Central, Bogotá, Colombia.
Article Synopsis
- - Two cases of chilblain lupus erythematosus (CLE) were reported that may have been triggered by ultraviolet (UV) nail lamps.
- - The cases, alongside existing literature, indicate a potential connection between the use of UV nail lamps and the development or reactivation of CLE.
- - More research is necessary to verify this link, but healthcare providers should be cautious about the risks associated with UV nail lamps, particularly for patients with conditions sensitive to light.
Hereditary C1q Deficiency is Associated with Type 1 Interferon-Pathway Activation and a High Risk of Central Nervous System Inflammation.
J Clin Immunol
August 2024
Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Paris, France.
Article Synopsis
- Hereditary C1q deficiency (C1QDef) is a rare genetic disorder that disrupts the complement system and can cause symptoms similar to systemic lupus erythematosus (SLE).
- A study of 12 genetically confirmed C1QDef patients showed elevated expression of interferon-stimulated genes and high levels of interferon alpha in their blood and cerebrospinal fluid, indicating significant immune dysfunction.
- Treatment with Janus-kinase inhibitors had mixed results, with one patient improving while others continued to struggle with their condition, highlighting the complexity of managing C1QDef.
Diagnosis and management of COVID toes in outpatients: a case report.
J Med Case Rep
June 2024
University Center for Primary Care and Public Health, Unisanté, Lausanne, Switzerland.
Article Synopsis
- The most common skin condition linked to COVID-19 is pseudochilblains, commonly referred to as "COVID toes," which are hard to diagnose without a specific test.
- Two women, aged 30 and 22, were treated for these lesions during the pandemic; neither showed respiratory symptoms, but one had positive serology and both had distinct clinical difficulties post-cold exposure.
- Their cases highlight the variability of COVID-19 symptoms, suggesting that skin lesions may indicate an interferon response and should be considered in diagnoses during primary care visits.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!